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Background: Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and
dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim
and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in lower risk MDS patients
receiving lenalidomide.
Methods: Patients were assigned to weekly placebo (n = 12) or romiplostim 500 μg (n = 14) or 750 μg (n = 13) for
four 28-day lenalidomide cycles.
Results: The treatment groups were generally similar with respect to baseline disease characteristics. Del(5q)
abnormalities were noted in 1 (8%) patient in the placebo group, 3 (21%) in the romiplostim 500 μg group, and
two (15%) in the 750 μg group. CSTEs were noted in 8 (67%) patients in the placebo group, 4 (29%) in the
romiplostim 500 μg group, and 8 (62%) in the romiplostim 750 μg group. Throughout the study, median platelet
counts trended lower in placebo-treated than in romiplostim-treated patients. Thrombocytopenia-related
adjustments in lenalidomide occurred in 6 (50%) patients in the placebo group, 5 (36%) in the romiplostim 500 μg
group, and 2 (15%) in the 750 μg group. Although the percentages of patients who received platelet transfusions
were similar across treatment groups, there was a trend toward lower numbers of transfusions in both romiplostim
groups during each treatment cycle. There were two serious treatment-related adverse events during the treatment
period (cerebrovascular accident, placebo; worsening thrombocytopenia, romiplostim 500 μg). Two patients
(romiplostim 500 and 750 μg, respectively) had an increase in bone marrow blasts to >20% during treatment, but
had no post-treatment biopsy to confirm or exclude the diagnosis of progression to AML.
Conclusions: These data suggest that romiplostim administered to MDS patients during lenalidomide treatment
may decrease the frequency of dose reductions/delays due to thrombocytopenia. Additional study is needed to
confirm the results of this preliminary trial.
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Myelodysplastic syndromes (MDS) encompass a hetero-
geneous group of malignancies of hematopoietic pro-
genitor cells. MDS is characterized by stem-cell-derived
clonal myelopoiesis, hypercellular bone marrow with
dysplastic changes, ineffective hematopoiesis, and
increased apoptosis resulting in peripheral cytopenias
[1-3]. MDS is one of the most common hematologic ma-
lignancies in older individuals [1], with an annual inci-
dence between 75 and 162 per 100,000 persons 65 years
or older [4,5]. Patients often present with complications
related to anemia (fatigue), neutropenia (infections),
and/or thrombocytopenia (bleeding). Over the course of
the disease, thrombocytopenia occurs in 40–65% of
patients with MDS and can result in serious
hemorrhagic complications, leading to death in 14–24%
of patients [6]. Worsening thrombocytopenia is closely
linked to the underlying MDS disease biology and has
been associated with higher risk of transformation to
acute myeloid leukemia (AML) and lower overall sur-
vival [7,8]. Currently, platelet transfusion and aminoca-
proic acid are the only supportive treatments for
thrombocytopenia in MDS patients.
The pathogenesis of MDS is incompletely understood
but involves genetic, epigenetic, and immune-mediated
mechanisms [9]. Chromosomal aberrations are found in
half of patients at diagnosis [9]. Interstitial deletion of
the long arm of chromosome 5 (del[5q]) is the most fre-
quently reported cytogenetic aberration in MDS and has
been reported in up to 15% of cases [10,11]. Lenalido-
mide [12], an immunomodulatory agent, is approved for
the treatment of patients with MDS associated with del
(5q) on the basis of results of prior studies demonstrat-
ing that this agent resulted in transfusion independence
in 67% of treated patients [13]. However, treatment-
related thrombocytopenia occurs in 44–74% of
lenalidomide-treated MDS patients [13,14]. Because
this myelosuppression is dose dependent, cytopenias
constitute the most common reason for lenalidomide
dose adjustments, which have been reported in up to
84% of treated MDS patients [13,15]. In a study of
the relationship between lenalidomide-related cytope-
nias and treatment response, thrombocytopenia was
predictive of red blood cell transfusion independence
(TI) in lower risk MDS patients with del(5q) [16].
This finding suggests that response to lenalidomide
depends on effective suppression of the MDS clone
[16]. Given that thrombocytopenia is common in
MDS patients responding to lenalidomide and reflects
the pharmacological activity of the drug, concomitant
treatment with a thrombopoietic agent to reduce clin-
ically significant bleeding events related to low platelet
counts may be of significant benefit to affected MDS
patients.Romiplostim is a Fc-peptide fusion protein (peptibody)
that increases platelet production by binding to and acti-
vating the thrombopoietin receptor initiating megakar-
yopoiesis [17]. It has no sequence homology to
thrombopoietin. Romiplostim is indicated for the treat-
ment of thrombocytopenia in patients with chronic im-
mune thrombocytopenia (ITP) who have had an
insufficient response to corticosteroids, immunoglobu-
lins, or splenectomy [18]. It has been investigated for
treatment of MDS patients with or without del (5q) [19-
23]. In phase 1/2 studies, 46–65% of lower-risk throm-
bocytopenic MDS patients receiving romiplostim
achieved an International Working Group (IWG)-
defined platelet response [19,20,24]. In other studies, ad-
ministration of romiplostim in combination with
methyltransferase inhibitors appeared to confer thera-
peutic benefits in patients with low- or intermediate 1/
2-risk (per IPSS score) MDS [23,25].
We conducted this study to evaluate the safety and
tolerability of romiplostim and its effects on the inci-
dence of clinically significant thrombocytopenic events
(CSTEs) in patients with low or intermediate-1-risk
(“lower-risk”) MDS receiving lenalidomide therapy.
Methods
Study design and ethical considerations
This phase 2, multicenter, randomized, double-blind,
placebo-controlled study was conducted at 24 centers
throughout the United States from March 2007 to
March 2009. The protocol was reviewed and approved
by the appropriate institutional review board at each
center before any patients were recruited. The trial was
conducted in accordance with the principles of the Food
and Drug Administration (FDA) and International Con-
ference on Harmonisation (ICH) Good Clinical Practice
(GCP) regulations/guidelines. This trial was registered at
www.clinicaltrials.gov as #NCT00418665.
The study consisted of a double-blind treatment
period, during which patients received four 28-
day cycles of lenalidomide plus weekly injections of pla-
cebo or romiplostim, and an optional open-label exten-
sion period, during which patients could receive
lenalidomide plus romiplostim. Patients returned to the
center weekly during the treatment period, and again
1 day after the end of the fourth lenalidomide cycle for a
follow-up visit. Patients who completed the 16-week
treatment period continued lenalidomide and discontin-
ued romiplostim for at least 4 weeks prior to returning
for an end-of-treatment visit at week 20. After this visit,
patients could continue lenalidomide and were eligible
to receive romiplostim in the optional open-label exten-
sion period. All patients who entered the extension
period had an end-of-study visit 4 weeks after the last
dose of romiplostim. After the extension phase, patients
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label extension study [21]. Written, informed consent
was obtained from all patients or a legally acceptable
representative before any study-specific procedures were
performed.
Patients
Adult patients were eligible to participate in the study if
they had a diagnosis of MDS based on World Health
Organization (WHO) 2001 classification of marrow find-
ings [26] with IPSS lower-risk MDS disease [27], an
Eastern Cooperative Oncology (ECOG) performance sta-
tus of 0–2, and adequate liver and kidney function. All
patients agreed to receive ≥ 4 cycles of lenalidomide cap-
sules 10 mg by mouth daily. Patients were excluded if
they had previous exposure to > 3 cycles of lenalidomide
or exposure to lenalidomide within the last 30 days, or if
they had a history of leukemia or aplastic anemia, stem
cell transplantation, or prior malignancy (other than in
situ cervical cancer or basal cell cancer of the skin) un-
less treated with curative intent and without evidence of
disease for ≥3 years before randomization. Patients who
had active or uncontrolled infections, uncontrolled car-
diovascular disease, or a history of arterial or venous
thrombosis within the past year were also excluded, as
were patients who had received IL-11 within 4 weeks of
screening, any investigational drug or device < 4 weeks
previously, or any other thrombopoietic growth factor.
Randomization and treatment
Patients were assigned identification numbers from an
interactive voice response system (IVRS) and randomly
assigned in a 1:1:1 ratio to receive placebo or romiplos-
tim 500 μg or 750 μg. Patients were stratified by baseline
platelet count (≥ 50 × 109/L or < 50 × 109/L). During the
treatment period, all patients received a 10-mg lenalido-
mide capsule orally each day for four 28-day cycles, for a
planned total dose of 1120 mg; doses were reduced or
delayed when necessary as directed in the product label-
ing [12]. In addition, patients received subcutaneous
injections of placebo or romiplostim 500 μg or 750 μg
each week for 16 weeks. If a patient had a platelet count
> 450 × 109/L, investigational product was withheld until
the platelet count fell to < 200 × 109/L. Once the platelet
count fell to < 200 × 109/L, investigational product was
resumed on the next scheduled dosing day. Patients
whose dose of lenalidomide was delayed continued to
receive their weekly doses of romiplostim. Patients who
were thrombocytopenic for ≥ 4 weeks after discontinu-
ation of romiplostim could resume romiplostim treat-
ment whether or not they were receiving lenalidomide.
During the open-label extension, patients who had
received romiplostim during the treatment period
remained on the same dose, and patients who hadreceived placebo began treatment with romiplostim
500 μg. All patients continued lenalidomide 10 mg daily.
If a patient discontinued lenalidomide, romiplostim was
also discontinued temporarily. Patients who became
thrombocytopenic (as evidenced by an average of at least
two platelet counts ≤ 50 × 109/L with one count on the
day romiplostim was restarted) at least 4 weeks after the
last dose of romiplostim and lenalidomide could remain
on study and restart romiplostim at a dose of 750 μg
weekly until the end of the extension period.
During the double-blind portion of the study, investi-
gational product was packaged in two identical vials for
each scheduled dose for each patient. Patients received
1.5 mL of investigational product in each dose—1 mL
from one vial and 0.5 mL from the second vial. Patients
in the 500 μg group received 1 mL of romiplostim and
0.5 mL of placebo, patients in the 750 μg group received
1.5 mL of romiplostim, and patients in the placebo
group received 1.5 mL of placebo.
Throughout the study, investigators were allowed to
prescribe any concomitant medications or treatments
deemed necessary to provide adequate supportive care
except for the following: any medication known or sus-
pected to affect platelet production, immunomodulatory
agents, histone deacetylase inhibitors, cyclosporine,
mycophenolate, any myelosuppressive chemotherapy
other than lenalidomide, and any other investigational
product. Rescue medication, defined as any medication,
including platelet transfusions, administered to raise
platelet counts, was given only when a patient was at
immediate risk.
Assessments
Throughout the treatment and extension periods,
patients returned to the study center weekly for adminis-
tration of investigational product and review of adverse
events, bleeding events, and concomitant medications.
During the treatment period, samples were drawn
weekly for complete blood counts (including platelet
counts and differential) and blood chemistry analyses.
Blood samples were also intermittently collected for tests
for antibodies to romiplostim. Bone marrow biopsy and
aspirate samples were obtained for assessment of bone
marrow reticulin or collagen formation and cytogenetics
at the screening and end-of-treatment visits. Progression
to AML was determined on the basis of a marrow or
peripheral blast cell count ≥ 20% with confirmation
4 weeks after withdrawal of romiplostim. During the ex-
tension period, samples were drawn weekly for platelet
counts, every 2 weeks for complete blood counts and
differential, and every 4 weeks for blood chemistry ana-
lyses. Blood samples were collected for tests for anti-
bodies to romiplostim at weeks 1, 17, and 33 and at the
end-of-study visit, and for cytogenetics at the end-of-
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were also collected at the end-of-study visit.
Data analysis
The proposed sample size was 12 patients per group.
CSTEs were defined as (a) any platelet count obtained
from week 3 of cycle 1 through the follow-up visit that
was < 50 × 109/L and/or (b) the receipt of a platelet
transfusion at any time through the follow-up visit. The
distance from the observed difference to the sides of the
95% confidence intervals (95% CIs) was 0.362, with the
assumption that the rates of CSTEs would be 20% for
romiplostim and 50% for placebo.
No formal hypothesis testing was planned for this
dose-finding study. Descriptive statistics for demo-
graphic and baseline characteristics, safety, and efficacy
were summarized for all patients. For categorical vari-
ables, the number and percentage of patients in each
category were summarized. Continuous variables were
summarized by number, mean, standard deviation (SD),
median, Q1 (25th percentile), Q3 (75th percentile), and
minimum and maximum values. For efficacy variables,
95% exact binomial confidence intervals for the inci-
dence were provided for each treatment group and for
the difference between treatment groups. The Mantel-
Haenszel common odds ratios controlling for baseline
platelet counts were estimated along with 95% confi-
dence intervals. Additional summary by del(5q) status
was also provided.
Efficacy analyses were performed using the set of all
randomized patients. Patients who discontinued the
study before the occurrence of an event were considered
not to have had the event and were included in the ana-
lysis unless otherwise noted. The primary efficacy end-
point was the percentage of patients who had a CSTE.
Additional efficacy endpoints included the percentage of
patients who had a reduction or delay in lenalidomide
dose due to thrombocytopenia during the treatment
period; the percentage of patients who received ≥ 1
platelet transfusions and the total number of units admi-
nistered during the treatment period; the percentage of
patients who had a complete response (CR), partial re-
sponse (PR), or overall response (CR + PR) at the end of
the treatment period based on the 2006 modified IWG
guideline [28]; and the incidence of bleeding events. The
exposure-adjusted bleeding event rates were provided
with 95% CIs. Post hoc endpoints included the propor-
tion of patients whose platelet counts were < 20 × 109/L
at any point during the treatment cycle or overall, by
baseline platelet count and for all patients, and the per-
cent decreases in platelet counts from day 1 of the treat-
ment cycle to the nadir for each treatment cycle.
Safety analyses were performed using the set of
patients who received at least one dose of investigationalproduct. Patients were analyzed according to the treat-
ment actually received. Safety was assessed on the basis
of the incidence of adverse events, anti-romiplostim
antibody formation, and formation of antibodies that
cross-react with endogenous thrombopoietin (eTPO).
Results
Patients
Of the 39 patients randomized, 12 were assigned to re-
ceive weekly placebo, 14 to receive weekly romiplostim
500 μg, and 13 to receive weekly romiplostim 750 μg.
The median (range) age of the patients was 74 (39–90)
years, and 62% were male (Table 1). The treatment
groups were generally similar with respect to baseline
disease characteristics (Table 1). Six patients (15%) had
MDS characterized by del(5q) abnormalities: one in the
placebo group, three in the romiplostim 500 μg group,
and two in the 750 μg group. Two patients, one each
from the placebo and romiplostim 500 μg groups, were
deemed ineligible for the study because they had an IPSS
score > 1.0 (“higher-risk”). Although these patients did
not receive any investigational product, they were
included in the analyses of efficacy. Two patients rando-
mized to the placebo group each erroneously received
one dose of romiplostim during the treatment period.
These patients are included in the placebo group of the
efficacy analysis set and in the romiplostim group of the
safety analysis set.
A total of 24 patients completed the treatment period,
and 13 (33%) discontinued (Figure 1). The most com-
mon reasons for discontinuation were adverse event,
withdrawal of consent, and administrative decisions,
each occurring in four (10%) patients. Eighteen (46%)
patients entered the optional extension period, and 12
(31%) discontinued during the extension period. The
baseline characteristics of the patients who entered the
extension period were similar to those of the patients
who entered the initial treatment period. During
the extension period, the most common reasons for
discontinuation were requirement for alternative ther-
apy in 4 (10%) patients and administrative decisions in
5 (13%). One patient in the romiplostim 750 μg group
died during the extension period from intestinal ob-
struction, which was not considered related to
romiplostim.
During the treatment period, the median (range) num-
ber of doses of investigational product was 16 (6–16) in
the placebo group, 16 (4–16) in the romiplostim 500 μg
group, and 16 (10–16) in the romiplostim 750 μg group.
The median (range) average romiplostim dose was 391
(31–500) μg in the 500 μg group and 622 (47–750) μg in
the 750 μg group. The median (range) duration of lenali-
domide exposure was 19 (6–20) weeks in the placebo
group, 18 (4–19) weeks in the romiplostim 500 μg
Table 1 Demographic characteristics
Baseline demographics, n (%) Placebo Romiplostim Total
500 μg 750 μg
(N = 12) (N = 14) (N = 13) (N = 39)
Sex – Male, n (%) 8 (67) 8 (57) 8 (62) 24 (62)
Race – White or Caucasian, n (%) 11 (92) 13 (93) 12 (92) 36 (92)
Age (years), median (range) 79 (39–87) 75 (49–90) 65 (49–83) 74 (39–90)
Platelets (× 109/L), n (%)
<50 × 109/L 5 (42) 5 (36) 5 (39) 15 (39)
≥50 × 109/L 6 (50) 8 (57) 8 (62) 22 (56)
Unknown* 1 (8) 1 (7) 0 (0) 2 (5)
IPSS score, n (%)
0 4 (33) 4 (29) 6 (46) 14 (36)
0.5 3 (25) 6 (43) 4 (31) 13 (33)
1.0 3 (25) 2 (14) 3 (23) 8 (21)
1.5† 1 (8) 1 (7) 0 (0) 2 (5)
Unknown* 1 (8) 1 (7) 0 (0) 2 (5)
MDS duration (y), median (range) 2.6 (0–9) 0.5 (0–6) 0.5 (0–7) 0.6 (0–9)
MDS diagnosis - n (%)
RA 1 (8) 0 (0) 0 (0) 1 (3)
RARS 2 (17) 2 (14) 2 (15) 6 (15)
RAEB-1 2 (17) 3 (21) 3 (23) 8 (21)
RCMD 4 (33) 4 (29) 4 (31) 12 (31)
RCMD-RS 0 (0) 0 (0) 1 (8) 1 (3)
MDS-U 1 (8) 1 (7) 1 (8) 3 (8)
MDS associated with isolated del(5q) 1 (8) 3 (21) 2 (15) 6 (15)
Unknown* 1 (8) 1 (7) 0 (0) 2 (5)
Cytogenetic findings‡
Normal/diploid 8 (67) 7 (50) 10 (77) 25 (64)
+8 1 (8) 2 (14) 1 (8) 4 (10)
-Y 2 (17) 1 (7) 0 3 (8)
del(5q) 1 (8) 3 (21) 2 (15) 6 (15)
del(7q) 0 1 (7) 0 1 (3)
del(12p) 1 (8) 1 (7) 0 2 (5)
Other 1 (8) 0 0 1 (3)
Complex (>3 abnormalities) 0 0 0 0
Unknown 1 (8) 1 (7) 0 2 (5)
Legend: del 5q deletion 5q cytogenetic abnormality, IPSS International Prognostic Scoring System, MDS myelodysplastic syndrome, MDS-U myelodysplastic
syndrome, unclassified, RA refractory anemia, RAEB refractory anemia with excess blasts, RARS refractory anemia with ringed sideroblasts, RCMD refractory
cytopenia with multilineage dysplasia, RCMD-RS refractory cytopenia with multilineage dysplasia and ringed sideroblasts.
*Information not available for two ineligible patients.
†Patients permitted to enter study despite protocol violation of IPSS score greater 1.0 (protocol violation).
‡Patients could have more than one abnormality (and so could be counted more in more than one row).
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group. The median (range) total cumulative doses of
lenalidomide were 705 (290–1350) mg in the placebo
group, 893 (160–1340) mg in the romiplostim 500 μg
group, and 745 (280–1500) mg in the romiplostim
750 μg group.Efficacy
CSTEs were noted in 8 (67%) patients in the placebo
group, 4 (29%) in the romiplostim 500 μg group (esti-
mated difference from placebo group −38%; 95% CI,
-74%, -2%), and 8 (62%) in the romiplostim 750 μg
group (estimated difference from placebo group -5%;
Figure 1 Patient disposition.
Table 2 Clinical outcomes by baseline platelet count and deletion(5q) cytogenetic abnormality status
Efficacy variables Placebo Romiplostim
500 μg 750 μg
N*,† n (%) N* n (%) N n (%)
Clinically significant thrombocytopenic event‡
Overall 12 8 (67) 14 4 (29) 13 8 (62)
Baseline platelets <50 × 109/L 5 5 (100) 5 2 (40) 5 5 (100)
Baseline platelets ≥50 × 109/L 6 3 (50) 8 2 (25) 8 3 (38)
Del(5q) detected at baseline 1 0 (0) 3 0 (0) 2 0 (0)
Lenalidomide dose reduction or delay§
Overall 12 6 (50) 14 5 (36) 13 2 (15)
Baseline platelets <50 × 109/L 5 3 (60) 5 1 (20) 5 0 (0)
Baseline platelets ≥50 × 109/L 6 3 (50) 8 4 (50) 8 2 (25)
Del(5q) detected at baseline 1 1 (100) 3 0 (0) 2 0 (0)
Achieved MDS treatment response¶
Overall 12 1 (8) 14 2 (14) 13 3 (23)
Patients with baseline platelets <50 × 109/L 5 0 (0) 5 1 (20) 5 0 (0)
Patients with baseline platelets ≥50 × 109/L 6 1 (17) 8 1 (13) 8 3 (38)
Del(5q) detected at baseline 1 0 (0) 3 1 (33) 2 1 (50)
Achieved erythroid response∥
Overall 6 2 (33) 7 2 (29) 8 2 (25)
Baseline platelets <50 × 109/L 3 1 (33) 2 0 (0) 4 1 (25)
Baseline platelets ≥50 × 109/L 3 1 (33) 5 2 (40) 4 1 (25)
* Includes 1 patient who was found to be ineligible for the study after randomization and did not receive treatment.
† Includes two patients who erroneously received one dose of romiplostim (500 μg and 750 μg, respectively) during the treatment period.
‡ Clinically significant thrombocytopenic events were defined as a platelet count <50 × 109/L starting at from week 3 of cycle 1 of treatment or receipt of platelet
transfusion at any time. Patients who were randomized but later found to be ineligible were counted as not having a clinically significant thrombocytopenic event.
§ Patients who were randomized but later found to be ineligible were counted as not having any lenalidomide dose reductions or delays.
¶ Complete or partial response based on 2006 modified IWG guideline [28]. Patients who were randomized but later found to be ineligible were counted as not
having achieved an MDS treatment response.
∥ Erythroid response is defined based on the modified IWG criteria as hemoglobin increase by ≥1.5 g/dL or relevant reduction in units of red blood cell
transfusions by an absolute number of ≥4 red blood cell transfusions/8 weeks.
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was observed. In all three treatment groups, the percent-
age of patients who experienced CSTEs trended higher
among patients who had baseline platelet counts < 50 ×
109/L (Table 2). No CSTEs were reported in patients
with del(5q).
Overall, reductions or delays in lenalidomide dosing
due to thrombocytopenia were reported in 6 (50%)
patients in the placebo group, 5 (36%) in the romiplos-
tim 500 μg group, and 2 (15%) in the romiplostim
750 μg group (Table 2). In the two romiplostim groups,
lenalidomide doses were reduced or delayed in a greater
proportion of patients with baseline platelet counts ≥
50 × 109/L than in patients with lower baseline platelet
counts; none of these patients with dose reductions/
delays had del(5q) at baseline.
An overall MDS treatment response was reported in 1
(8%) patient in the placebo group, 2 (14%) in the romi-
plostim 500 μg group, and 3 (23%) in the 750 μg group
(Table 2). Erythroid response was achieved in similar
percentages of patients in the three treatment groups
(Table 2).
Overall, the percentages of patients who received
platelet transfusions were similar in the three treatment
groups: 33% in the placebo, 29% in the romiplostim
500 μg, and 31% in the romiplostim 750 μg group. As-
sessment by treatment cycle showed that the percen-
tages of patients who received transfusions in the
romiplostim groups trended lower than in the placebo
group during all four cycles. None of the patients in the
500 μg group received a platelet transfusion after the
second cycle of treatment. In the romiplostim 500 μg
group, the total number of platelet transfusions adminis-
tered and the total platelet units transfused trended
lower than in the placebo group during each cycle
(Figure 2). In the 750 μg group, the total number of
platelet transfusions administered and the total unitsFigure 2 Platelet transfusions administered. A) Total platelet units receireceived were generally similar to those in the placebo
group (Figure 2).
Median platelet counts were consistently higher in the
romiplostim groups than in the placebo group through-
out the treatment period (Figure 3). In the placebo
group, median platelet counts generally fluctuated
around 50 × 109/L through week 12 and then remained
below 50 × 109/L. In the romiplostim 500 μg group, after
the first 2 weeks, median platelet counts generally fluc-
tuated between 150 and 250 × 109/L. In the romiplostim
750 μg group, the median platelet count increased to
344 × 109/L after 4 weeks and then fluctuated between
70 and 200 × 109/L.
Among patients whose baseline platelet counts were <
50 × 109/L, none of the patients in the romiplostim
500 μg group had platelet counts < 20 × 109/L during
the treatment period, and the percentages of patients in
the romiplostim 750 μg group with platelet counts <
20 × 109/L during the treatment period trended lower
than in the placebo group except during cycle 2
(Figure 4A). No patients with baseline platelet counts ≥
50 × 109/L had a drop in platelet counts to under 20 ×
109/L during cycle 1. During cycles 2 through 4, the per-
centages of patients with platelet counts < 20 × 109/L in
the romiplostim groups trended lower than in the pla-
cebo group and remained under 15%. Overall, the per-
centages of patients with platelet counts < 20 × 109/L
trended lower in both romiplostim groups than in the
placebo group during each treatment cycle (Figure 4B).
The median percent decrease from the platelet count
at day 1 to the nadir of each cycle is shown for all
patients in Figure 4C. In the romiplostim 500 μg group,
these decreases trended smaller than in the placebo
group during all cycles but cycle 2 in patients with base-
line platelet counts < 50 × 109/L and during all cycles in
patients with baseline platelet counts ≥ 50 × 109/L. In
the romiplostim 750 μg group, the median decreasesved and B) total number of platelet transfusions administered.
Figure 3 Median platelet counts during the treatment period. Bars of line graph represent standard deviations. Broken horizontal line is at
50 × 109/L.
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all cycles except for cycle 2. During the extension period,
median platelet counts generally fluctuated between 50
and 100 × 109/L (Figure 5).
Bleeding events were reported in one patient in the
placebo group, four in the romiplostim 500 μg group,
and four in the 750 μg group. The number (95% CI) of
bleeding events reported per 100 patient-weeks was 4.8
(2.1, 9.6) in the placebo group, 2.6 (0.8, 6.1) in the romi-
plostim 500 μg group, and 8.1 (4.7, 13.0) in the romi-
plostim 750 μg group.
Safety
During the treatment period, adverse events were
reported by all but one patient in the placebo group and
by all patients in the romiplostim groups (Table 3). The
most frequently reported adverse events were diarrhea,
thrombocytopenia, neutropenia, and dizziness in the pla-
cebo group; thrombocytopenia, diarrhea, rash, and con-
stipation in the romiplostim 500 μg group; and fatigue,
diarrhea, rash, and nausea in the romiplostim 750 μg
group. Adverse events led to study withdrawal or investi-
gational product discontinuation in 3 (33%) patients in
the placebo group, 2 (14%) in the romiplostim 500 μg
group, and 1 (7%) in the romiplostim 750 μg group.
These adverse events were pancytopenia, asthenia, and
cerebrovascular accident in the placebo group; pancyto-
penia and rash in the romiplostim 500 μg group; and
thrombocytopenia in the romiplostim 750 μg group.
Only cerebrovascular accident in the placebo group was
considered related to investigational product. Adverse
events of severity grade ≥ 3 were reported in 6 (67%)patients in the placebo group, 9 (64%) in the romiplos-
tim 500 μg group, and 10 (71%) in the romiplostim
750 μg group. Serious adverse events were reported in 6
(67%) patients in the placebo group, 5 (36%) in the romi-
plostim 500 μg group, and 4 (29%) in the romiplostim
750 μg group. Only two serious events, cerebrovascular
accident in one patient in the placebo group and wor-
sening thrombocytopenia in one patient in the romiplos-
tim 500 μg group, were considered related to treatment.
In the latter patient, worsening thrombocytopenia
(platelet count of 10 × 109/L) was noted at the patient’s
end-of-treatment visit, 4 weeks after her last dose of
romiplostim during the treatment period. When romi-
plostim treatment was resumed during the extension
period, her platelet counts increased from 17 × 109/L at
extension week 1 to 86 × 109/L at extension week 16,
when romiplostim was discontinued because of an ad-
ministrative decision.
During the extension period, the safety profiles of the
investigational products were similar to those during the
treatment period. Serious adverse events were reported
in 4 (22%) patients. Of these events, only leukocytosis,
reported in one patient who had received placebo during
the treatment period, was considered related to investi-
gational product. One patient in the romiplostim 750 μg
group died during the extension period from an
intestinal obstruction, which was not considered related
to investigational product. No patients developed neu-
tralizing antibodies to romiplostim or thrombopoietin.
For the 37 patients who had available screening and
end-of-treatment bone marrow biopsy data, no patients
exhibited changes in trichrome stain indicative of
Figure 4 Changes in platelet counts over treatment. A) Proportion of patients with baseline platelet count <50 × 109/L whose platelet counts
were <20 × 109/L at any point during the treatment cycle or overall. B) Percentages of patients with platelet counts <20 × 109/L at any point
during the treatment cycle. C) Median percent decrease from the platelet count at day 1 to the nadir of each treatment cycle for all patients.
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Figure 5 Median platelet counts during the extension period.
Bars represent interquartile ranges. Broken horizontal line is at 50 ×
109/L.
Table 3 Number (%) of patients who reported adverse events
n (%) P
(
Any adverse event (AE) §
Grade 3
Grade 4


















AE leading to study withdrawal or IP discontinuation
Legend: AE adverse event, SAE serious adverse event, IP investigational product.
* The placebo group of the safety analysis set included the nine patients who recei
† The romiplostim 500 μg group of the safety analysis set included the 13 patients
originally randomized to the placebo group who inadvertently received one dose o
‡ The romiplostim 750 μg group of the safety analysis set included the 13 patients
originally randomized to the placebo group who inadvertently received one dose o
§ No Grade 5 adverse events were reported.
¶ This event was reported 4 weeks after the patient’ s last dose of romplostim durin
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http://www.jhoonline.org/content/5/1/71collagen fibrosis formation. No clinically meaningful
differences were detected in bone marrow reticulin/
collagen formation between placebo and romiplostim
treatment groups.
No patients met the study-defined criteria for disease
progression to AML (i.e., marrow or peripheral blast cell
count ≥ 20% with confirmation 4 weeks after withdrawal
of romiplostim) during the treatment or extension
period. Two patients, one in the romiplostim 500 μg
group and the second in the romiplostim 750 μg group,
were reported as having an increase in bone marrow
blasts to greater than 20%, consistent with the WHO
definition of AML, but both were receiving romiplostim
at the time of the blast increase. The patient in the
500 μg group at study entry was a 63-year-old woman
with an IPSS score of 1.5 (whose entry into the trial was
due to a protocol violation), a WHO classification ofduring the treatment period
lacebo Romiplostim
500 μg 750 μg
N = 9)* (N = 14) † (N = 14) ‡
8 (89) 14 (100) 14 (100)
5 (56) 5 (36) 8 (57)
1 (11) 4 (29) 2 (14)
1 (11) 4 (29) 8 (57)
3 (33) 7 (50) 3 (21)
5 (56) 5 (36) 5 (36)
2 (22) 5 (36) 5 (36)
0 (0) 4 (29) 5 (36)
2 (22) 7 (50) 5 (36)
6 (67) 5 (36) 4 (29)
0 (0) 3 (21) 1 (7)
0 (0) 1 (7) 2 (14)
0 (0) 2 (14) 0 (0)
0 (0) 1 (7) 1 (7)
0 (0) 1 (7) 1 (7)
1 (11) 1 (7) 0 (0)
1 (11) 0 (0) 0 (0)
0 (0) 1 (7) 0 (0)
0 (0) 0 (0) 0 (0)
3 (33) 2 (14) 1 (7)
ved only placebo during the treatment period.
treated with romiplostim 500 μg during the treatment period plus one patient
f romiplostim 500 μg during the treatment period.
treated with romiplostim 750 μg during the treatment period plus one patient
f romiplostim 750 μg during the treatment period.
g the treatment period.
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http://www.jhoonline.org/content/5/1/71RAEB-1, and a bone marrow blast count of 5%. Her
prognostic score, based on the paper by Garcia-Manero
et al., was 5 (category 3: median survival, 14.2 months;
4-year survival, 7%) [8]. At 2 months, her bone marrow
blast count had increased to 24%. Because of a concern
for possible disease progression, she withdrew her con-
sent and discontinued the study. She declined to
undergo a follow-up bone marrow biopsy. She died
1 year later. The second patient in the 750 μg group at
study entry was a 69-year-old woman with an IPSS score
of 1.0, a WHO classification of RAEB-1, and a bone
marrow blast count of 5%. Her prognostic score was 6
(category 3: median survival, 14.2 months; 4-year sur-
vival, 7%) [8]. Four days after her last dose of romiplos-
tim at week 16, her blast count had increased to 29%.
She discontinued the study 3.5 weeks later because of
the increased blast count. The patient refused to
undergo an additional bone marrow biopsy. No add-
itional follow-up information is available.
Discussion
Analysis of the results of this study suggests that romi-
plostim can reduce the rate of CSTEs while increasing
platelet counts in lower risk MDS patients receiving
lenalidomide. These effects were reflected in trends to-
ward smaller percentages of patients requiring lenalido-
mide dose reductions or delays, higher percentages of
patients achieving MDS treatment response, and lower
percentages of patients receiving transfusions during
each lenalidomide cycle in the romiplostim groups than
in the placebo group. There was no observed romiplos-
tim dose response identified, possibly because of the
small numbers of patients in each treatment group.
The results of this study were consistent with those of
two previous studies in which MDS patients received
romiplostim in combination with the DNA methyltrans-
ferase inhibitors azacitidine or decitabine [23,25]. In
those studies, trends toward lower platelet transfusion
rates, higher platelet counts at the beginning and nadir
of each treatment cycle, and lower percentages of
patients with bleeding events in the romiplostim-treated
groups were observed. These results suggested that add-
ing romiplostim to methyltransferase inhibitor therapy
was associated with clinical benefits. Attempts to com-
pare our results with those of studies of romiplostim
monotherapy in MDS patients were confounded by dif-
ferences in study design, severity of disease in the
patients studied, and the outcome variables assessed
[19,20].
In this study, the overall MDS response to lenalido-
mide appeared to be modestly affected by romiplostim.
In previous reports, thrombocytopenia was shown to be
common among MDS patients receiving lenalidomide
and is postulated to constitute a predictive indicator oftherapeutic response [16], as well as a frequent cause of
lenalidomide dose reduction and interruption [13-15]. In
one study of lenalidomide in del(5q) MDS patients [13],
the duration of lenalidomide treatment was significantly
less in patients with baseline thrombocytopenia because
of recurring dosing interruptions due to myelosuppres-
sion. In that study, thrombocytopenia was a significant
predictor of a lower probability of transfusion independ-
ence. These findings suggest that duration of lenalido-
mide treatment is an important determinant of
hematologic improvement. In other studies, severe
thrombocytopenia in MDS patients treated with lenali-
domide generally occurred within the first two cycles,
with median times to dose adjustments ranging from 22
to 43 days [13-15]. Here in our study, romiplostim treat-
ment was associated with increases in platelet counts by
the third week of treatment, and lenalidomide dose
reductions or delays tended to be lower in patients trea-
ted with romiplostim. These effects may have contribu-
ted to the observed higher rates of MDS responses in
the romiplostim- versus placebo-treated groups.
Adverse events in this study were similar in the three
treatment groups, with only two serious events (cerebro-
vascular accident, worsening thrombocytopenia) consid-
ered treatment related. No neutralizing antibodies to
romiplostim were detected in any patients, and there
was no evidence of increased bone marrow reticulin or
collagen formation in individuals treated with drug. Al-
though possible transformation to AML was noted in
two patients, these patients did not meet protocol-
defined criteria for AML because of the lack of repeat
marrow evaluation after a 4-week drug washout period.
Moreover, the reported increases in marrow blasts were
noted in both patients while they were still receiving
romiplostim, which may transiently increase blast cell
counts [18]. Therefore, it remains unclear whether these
cases represent transient drug-related blast increases or
true AML progression. It is noteworthy that the data
monitoring committee recommended discontinuing in-
vestigational treatment in a previous randomized trial of
romiplostim in MDS patients [22]. At the time of inves-
tigational treatment discontinuation in that trial, a non-
significant numeric imbalance of AML cases was
observed; there were concerns that the potential small
benefit seen in the reduction of bleeding did not out-
weigh the potential risk for disease progression to AML
and that transient increases in blast cell counts may put
patients at risk for diagnosis of and treatment for AML.
As a result of these events, a second trial was modified
by Amgen administratively such that patients discontin-
ued romiplostim and entered long-term follow-up [21].
In conclusion, the results of this study suggest that
romiplostim may reduce the rate of CSTEs while in-
creasing platelet counts in lower risk MDS patients
Wang et al. Journal of Hematology & Oncology 2012, 5:71 Page 12 of 13
http://www.jhoonline.org/content/5/1/71receiving lenalidomide. Our data show that romiplostim
can decrease the frequency of lenalidomide dose reduc-
tions and delays due to thrombocytopenia and is poten-
tially associated with improved treatment responses.
Inferences drawn from this study are limited by the
small sample size, enrollment of patients with variable
degrees of baseline thrombocytopenia, and imbalances
in MDS disease characteristics between treatment
groups. Additional study is needed to confirm the results
of this preliminary trial.
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